Plant Visit Note India Pesticides



Capacity addition and product launches to drive growth

We visited India Pesticides' (IPL) Sandila facility located at Hardoi (Uttar Pradesh) and met the management for an update on its recent expansion and to gauge its growth prospects. IPL is the sole Indian manufacturer and ranks among the top five globally for several technicals such as Folpet, Captan, and Thiocarbamate herbicide. It has registered a revenue/profit CAGR of 26%/35% in the last five years. It is expanding capacity at its existing site (brownfield capex of INR140 over FY22–23) and setting up a greenfield project at Hamirpur (capex of INR100cr), which will start contributing in H2FY24. This capex may fetch a revenue of 2.5x of the investments. The management has guided at a 25% revenue CAGR over the next three years and an EBITDA margin of 22–25%. We maintain our positive stance on the stock. The stock is not rated. Here are the key takeaways from that interaction:

Commands healthy domestic and international market position in a few products

IPL is the sole domestic manufacturer and ranks among the top five producers globally for several technicals such as Folpet (fungicides), Captan (fungicides), and Thiocarbamate (insecticides). It leads in key herbicides (Prosulfocarb and Pretilachlor), fungicides (Ziram), and several other products. It caters to 95% of the domestic demand for Captan. IPL exports to more than 25 nations and aims to expand its global reach. In Q3FY23, it garnered 68% of revenue via exports.

Capacity addition and product launches to drive revenue and earnings growth

IPL has two manufacturing facilities at Dewa Road, Lucknow (technicals/formulation capacity of 2,100mtpa/3,000mtpa) and Sandila, Hardoi (technicals/formulation capacity of 21,400mtpa/3,500mtpa). It has set up a fourth block dedicated to herbicides (both intermediate and technical) at Sandila at a capex of INR70cr (peak revenue potential of INR200cr). With this, the total brownfield capex has touched INR140cr. It is also setting up a new project in Hamirpur (Uttar Pradesh) at a capex of INR100cr (spent: INR10cr) under its wholly-owned subsidiary Shalvis Specialty. It has received the necessary clearance from the Ministry of Environment, Forest and Climate Change. The facility is likely to commence operations by H2FY24, though optimization will occur in FY25.

The company has a diversified product portfolio across herbicides, insecticides, and pesticides. It has registered 28-30 technical molecules in India and more than 100/25 formulations in the domestic /export market. The management aims to launch a key herbicide with significant revenue potential in March. It is targeting five-to-six product launches annually to drive revenue growth.

Lion's share of the revenue from select marquee customers poses a concentration risk

In Q3FY23, IPL derived 84%/16% of revenue from technicals and API/formulations. The company caters to several marquee clients such as UPL, Syngenta, Sharda Cropchem, Rallis India, and Conquest (Australia). However, it is exposed to concentration risk as its top five/three customers contribute ~55%/~40% of revenue.

Adverse macro conditions impacted revenue in 9MFY23; things to improve going forward

IPL generated revenue of INR687cr in 9MFY23 (up 27.5% YoY). EBITDA margin contracted by 924bp YoY to 22.5%, resulting in a 10%/11% decline in EBITDA/PAT to INR155cr/INR113cr. A substantial increase in input cost and energy prices impacted profitability as a part of the increase in energy prices could not be passed on. While raw material costs remain firm, the energy cost has softened a bit in Q4FY23. We expect a YoY decline in earnings in FY23, though product launches and optimization of brownfield capex will drive strong performance in subsequent years. In FY22, abnormally high realization and volume growth resulted in an EBITDA margin of 30%. The management has guided at a 25% revenue CAGR over the next five years and an EBITDA margin of 22-24%.

Valuation and view

We remain positive on IPL given its positioning in key pesticides, retention of marquee clients, and a calibrated capex that is manageable through internal accruals. Headwinds (input and energy cost) that impacted its performance in 9MFY23 are likely to ease in FY24. A revival in demand from eastern Europe, product launches, and capacity expansions at Sandila and Hamirpur will drive revenue. Capex of INR240cr over FY22–23 should earn it a peak revenue of INR600cr on full utilisation over the current base of ~INR900cr. A cash surplus Balance Sheet and current FCF are sufficient to meet its proposed capex requirements. The management's guidance indicates a PAT of ~INR150cr/INR185cr/INR230cr in FY23/FY24/FY25 (assuming ~25% revenue growth and 22% EBITDA margin). The stock is trading at 16x/13x/10x FY23/FY24/FY25 EPS. The stock is not rated.

T. Ranvir Singh

ranvir.singh@nuvama.com

Harsh Shah

harsh.shah@nuvama.com

CMP: INR 217
Rating: NOT RATED
Date: March 23, 2023

Bloomberg:	SNLL:IN
52-week range (INR):	197/331
M-cap (INR cr):	2,418
Promoter holding (%)	67.20



Quarterly Update

Particulars	Q3FY23	Q3FY22	% change	Q2FY23	% change
Income from operations	218	190	15	251	-13
Cost of goods sold	120	85	41	143	-16
Gross Profit	97	105	-7	108	-9
Employee expenses	9	8	18	9	-1
Other expenses	42	36	16	46	-9
Total operating expenses	171	129	33	198	-14
EBITDA	47	61	-24	53	-11
Depreciation and amortisation	3	2	35	3	10
EBIT	43	59	-26	50	-13
Interest expenses	2	1	42	2	-12
Other income	5	1	245	2	94
Profit before tax	46	59	-22	50	-8
Provision for tax	12	16	-28	13	-11
Adjusted net profit	35	43	-19	37	-7
Extraordinary items	0	0		0	
Reported net profit	35	43	-19	37	-7
No. of shares (Cr)	11.5	11.5		12	
Diluted EPS (INR)	3.0	3.8	-19	3.2	-7



Financials

Income statement					(INR crs)
Year to March	FY18	FY19	FY20	FY21	FY22
Income from operations	248	341	480	649	716
Direct costs	143	218	309	360	378
Power & Fuel	13	17	22	28	33
Employee costs	12	13	16	23	30
Other expenses	24	27	38	55	62
Total operating expenses	193	275	386	466	502
EBITDA	55	65	94	183	214
Depreciation and amortisation	4	4	5	6	9
EBIT	52	61	88	177	205
Interest expenses	4	6	5	3	7
Profit before tax	50	61	93	180	212
Provision for tax	17	17	23	45	54
Extraordinary items	0	0	0	0	0
Profit after tax	33	44	71	135	158
Share from associates	0	0	0	0	0
Adjusted net profit	33	44	71	135	158
Equity shares outstanding (mn)	11.2	11.1	11.1	11.2	11.5
EPS (INR) basic	3	4	6	12	14
Diluted shares (Cr)	11.2	11.1	11.1	11.2	11.5
EPS (INR) fully diluted	3	4	6	12	14

Common size metrics- as % of net revenues

Year to March	FY18	FY19	FY20	FY21	FY22
Operating expenses	77.7	80.8	80.5	71.8	70.2
Depreciation	1.4	1.2	1.1	0.9	1.2
Interest expenditure	1.8	1.6	1.1	0.5	1.0
EBITDA margins	22.3	19.2	19.5	28.2	29.8
Net profit margins	13.2	12.9	14.8	20.7	22.1

Growth metrics (%)

Year to March	FY18	FY19	FY20	FY21	FY22
Revenues	8.8	37.3	40.8	35.3	10.4
EBITDA	(6.9)	17.9	43.3	95.7	16.8
PBT	(5.3)	21.7	52.9	92.7	17.6
Net profit	(7.5)	33.8	61.3	90.0	17.4
EPS	(7.5)	34.0	61.4	89.2	14.0



Balance sheet					(INR Cr)
As on 31st March	FY18	FY19	FY20	FY21	FY22
Equity share capital	3	3	3	11	12
Preference Share Capital	0	0	0	0	0
Reserves & surplus	141	184	254	378	626
Shareholders funds	144	187	257	389	638
Borrowings	46	61	28	30	23
Net Deferred tax	8	8	8	9	11
Minority interest	0	0	0	0	0
Sources of funds	197	256	293	429	672
Gross block	73	77	108	140	196
Depreciation	3	7	9	15	23
Net block	69	70	99	124	174
Capital work in progress	3	5	1	12	44
Total fixed assets	72	75	101	136	218
Investments	3	3	3	9	17
Inventories	19	36	39	70	140
Sundry debtors	125	178	183	214	248
Cash and equivalents	3	3	8	44	107
Loans and advances	13	17	25	40	56
Other current assets	0	0	0	0	0
Total current assets	161	233	255	368	550
Sundry creditors and others	42	61	72	85	117
Provisions	1	0	1	4	4
Total CL & provisions	43	61	73	88	121
Net current assets	118	172	182	279	429
Misc expenditure	5	6	7	4	8
Uses of funds	197	256	293	429	672
Book value per share (INR)	13	17	23	35	55
	0	0	0	-0	-0
Cash flow statement					(INR Cr)
Year to March	FY18	FY19	FY20	FY21	FY22
Net profit	35	44	71	135	157
Add: Depreciation	3	4	5	6	8
Add: Misc expenses written off	3	3	2	4	8
Add: Deferred tax	0	0	0	0	0
Gross cash flow	41	51	79	145	174
Less: Changes in W. C.	25	54	3	62	98
Operating cash flow	16	-3	75	83	76
Less: Capex	12	7	31	42	82
Free cash flow	4	-11	44	41	-6



Ratios

Year to March	FY18	FY19	FY20	FY21	FY22
ROAE (%)	26	27	32	42	31
ROACE (%)	32	30	37	52	40
Debtors (days)	184	191	139	120	126
Current ratio	4	3	3	4	4
Inventory (days)	28	38	29	39	71
Payable (days)	54	59	47	42	49
Cash conversion cycle (days)	158	170	122	118	149
Net Debt/EBITDA	1	1	0	0	0
Net debt/Equity	0	0	0	0	0

Valuation parameters

Year to March	FY18	FY19	FY20	FY21	FY22
Diluted EPS (INR)	2.9	3.9	6.4	12.0	13.7
Y-o-Y growth (%)	(7.5)	34.0	61.4	89.2	14.0
Diluted P/E (x)	96.3	71.9	44.5	23.5	20.6
Price/BV(x)	22.0	16.9	12.3	8.1	5.1
EV/Sales (x)	12.9	9.4	6.6	4.9	4.4
EV/EBITDA (x)	57.8	49.2	33.9	17.2	14.9
Basic EPS	2.9	3.9	6.4	12.0	13.7
Basic PE (x)	96.3	71.9	44.5	23.5	20.6



Nuvama Wealth and Investment Limited, Edelweiss House, Windsor Ln, Kolivery Village, MMRDA Area, Kalina, Santacruz East, Mumbai, Maharashtra 400098

Sandeep Raina

Head of Fundamental Research sandeep.raina@nuvama.com

Disclaimer



Nuvama Wealth and Investment Limited (Formerly known as Edelweiss Broking Limited) ("NWIL") or ("Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. The business of NWIL and its Associates (list available on www.nuvamawealth.com) are organized around five broad business groups: Credit including Housing and SME Finance, Commodities, Financial Markets, Asset Management and Life Insurance

Broking services offered by Nuvama Wealth and Investment Limited under SEBI Registration No. INZ 000005231. Name of the Compliance Officer: Mr. Pranav Tanna, Email address: complianceofficer.nwil@nuvama.com. Corporate Office Edelweiss House, Off CST Road, Kalina, Mumbai 400098. Tel 022 40094400, 40885757, 40886278

This Report has been prepared by Nuvama Wealth and Investment Limited (Formerly Edelweiss Broking Limited) [NWIL] in the capacity of a Research Analyst having SEBI Registration No. INH000011103 and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors.

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NWIL and associates / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. NWIL reserves the right to make modifications and alterations to this statement as may be required from time to time. NWIL or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. NWIL is committed to providing independent and transparent recommendation to its clients. Neither NWIL nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance. Th

NWIL shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, break down of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the NWIL to present the data. In no event shall NWIL be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the NWIL through this report. We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.

NWIL and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company(ies), mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. NWIL may have proprietary long/short position in the above mentioned scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with NWIL.

NWIL or its associates may have received compensation from the subject company in the past 12 months. NWIL or its associates may have managed or co-managed public offering of securities for the subject company in the past 12 months. NWIL or its associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. NWIL or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. NWIL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Research analyst or his/her relative or NWIL's associates may have financial interest in the subject company. NWIL, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs and Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Research analyst has served as an officer, director or employee of subject Company: No

 $\ensuremath{\mathsf{NWIL}}$ has financial interest in the subject companies: No

NWIL's Associates may have actual / beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report.

Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

NWIL has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

Subject company may have been client during twelve months preceding the date of distribution of the research report.

Disclaimer



There were no instances of non-compliance by NWIL on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. A graph of daily closing prices of the securities is also available at www.nseindia.com

Analyst Certification

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

DISCLAIMERS FOR INTERNATIONAL JURISDICTION

Disclaimer for U.S. Persons

The content of the website does not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services and/or shall not be considered as an advertisement tool. "U.S. Persons" are generally defined as a natural person, residing in the United States or any entity organized or incorporated under the laws of the United States. US Citizens living abroad may also be deemed "US Persons" under certain rules. THIS DOCUMENT IS INTENDED SOLELY TO PROVIDE INFORMATION TO THE QUALIFIED INSTITUTIONAL INVESTORS ONLY AND IS NOT MEANT FOR RETAIL INVESTORS. If you are not the intended recipient you must not copy, distribute, or take any action or place reliance on it. If you have received this communication by error, please notify the sender immediately. This communication is intended solely for the person to whom it is addressed and may contain confidential or privileged information. The document is intended to be educational only and not for a marketing or prospecting purpose. The views and opinions expressed as part of this presentation do not necessarily state or reflect those of Nuvama, its holding company(ies), subsidiaries and associates including entities in overseas jurisdictions.

The content of the website or any information contained therein must not be distributed, published, reproduced, or disclosed (in whole or in part) by recipients to any other person. The content of the website must not be acted on or relied on by persons who are not qualified institutional investor. Any investment or investment activity to which this website relates, is available only to qualified institutional investor and will be engaged only with qualified institutional investor. Any person who is not a qualified institutional investor should not act or rely on this website or any of its contents

Disclaimer for U.K. Persons:

The content of the website has not been approved by an authorized person within the meaning of the Financial Services and Markets Act 2000 ("FSMA"). In the United Kingdom, this document is intended for (a) persons who have professional experience in matters relating to investments falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005 (the "Order"); (b) persons falling within Article 49(2)(a) to (d) of the Order (including high net worth companies and unincorporated associations); and (c) any other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons"). THIS document IS INTENDED SOLELY TO PROVIDE INFORMATION TO THE QUALIFIED INSTITUTIONAL INVESTORS ONLY AND IS NOT MEANT FOR RETAIL INVESTORS. If you are not the intended recipient you must not copy, distribute, or take any action or place reliance on it. If you have received this communication by error, please notify the sender immediately. This communication is intended solely for the person to whom it is addressed and may contain confidential or privileged information. The content of the document is intended to be educational only and not for a marketing or prospecting purpose. The views and opinions expressed as part of this document do not necessarily state or reflect those of Nuvama, its holding company (ies), subsidiaries and associates including entities in overseas jurisdictions.

Disclaimer for Canadian Persons

The content of the website is NOT MEANT FOR RETAIL INVESTORS. IT IS INTENDED SOLELY TO PROVIDE INFORMATION TO THE PERMITTED CLIENTS ONLY (as defined in National Instrument 31-103 ("NI 31-103")) who are resident in the Province of Ontario, Canada (an "Ontario Permitted Client"). Any products or services described in this document are made available only in accordance with applicable Canadian securities law and only where they may be lawfully offered for sale. If the person accessing this document is not an Ontario Permitted Client, as specified above, then the recipient should not access the same. Nuvama and its group companies is relying on an exemption from the adviser and/or dealer registration requirements under NI 31-103 available to certain international advisers and/or dealers. Please be advised that (i) Nuvama and its group companies is not registered in the Province of Ontario to trade in securities nor is it registered in the Province of Ontario to provide advice with respect to securities; (ii) Nuvama's head office or principal place of business is located in India; (iii) all or substantially all of Nuvama's assets may be situated outside of Canada; (iv) there may be difficulty enforcing legal rights against Nuvama because of the above; and (v) the name and address of Nuvama Group's agent for service of process in the Province of Ontario is: Bamac Services Inc., 181 Bay Street, Suite 2100, Toronto, Ontario MSJ 2T3 Canada. The content of the website must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person. This communication must not be acted on or relied on by persons who are not PERMITTED CLIENTS. Any investment or investment activity to which this communication relates is available only to relevant persons and will be engaged in only with relevant persons who is not a PERMITTED CLIENTS should not act or rely on this communication or any of its contents.

Disclaimer for UAE Persons

The content of the website is INTENDED SOLELY TO PROVIDE INFORMATION TO THE INSTITUTIONAL QUALIFIED INVESTORS ONLY AND IS NOT MEANT FOR RETAIL INVESTORS. Further, the information in this document does not constitute a public offer of securities in the United Arab Emirates and is not intended to be a public offer. The website has not been approved by or filed with the Central Bank of the United Arab Emirates, the Securities and Commodities Authority of the United Arab Emirates or the Dubai Financial Services Authority. The content of the website must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person. The website must not be acted on or relied on by persons who are not INSTITUTIONAL QUALIFIED INVESTORS. Any investment or investment activity to which this communication relates is available only to relevant persons and will be engaged in only with relevant persons. Any person who is not a INSTITUTIONAL QUALIFIED INVESTORS should not act or rely on this communication or any of its contents. The content of the website must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person. The website must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only to relevant persons and will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.

Disclaimer for Australia Persons

Any information set out on the website is only intended for persons who are "Professional Investors" as described in Section 761(G) of the Corporations Act 2001 (as amended). It is not intended to for any other class of persons and may not be relied upon by such persons and is therefore not intended for private individuals or those who would be classified as Retail Clients. All information on the website is general information only and is not to be considered any form of advice (whether investment or otherwise) or a recommendation, solicitation, or an offer to purchase or sell investments or related financial products or any financial services. The receiver of the website should make their own decisions based upon their own financial objectives and financial resources and, if in any doubt, should seek advice from an appropriate independent advisor. Nuvama and its group companies does not hold an Australian Financial Services License and is not licensed in Australia to provide financial product advice or services and is relying on "limited connection relief exemption" when dealing with "Professional Investors" (Wholesale client category) in Australia.

Disclaimer



Disclaimer for Singapore Persons

The content of the website IS INTENDED SOLELY TO PROVIDE INFORMATION ONLY TO THE INSTITUTIONAL OR ACCREDITED INVESTORS ONLY AND IS NOT MEANT FOR RETAIL INVESTORS AS DEFINED UNDER THE SECURITIES AND FUTURES ACT "SFA". If you are not the intended recipient you must not copy, distribute, or take any action or place reliance on it. If you have received this communication by error, please notify the sender immediately. Any such information contained or discussed in the document is subject to change and Nuvama and its group companies shall not have any responsibility to maintain the information made available or to supply any correction therewith. In no event will Nuvama and its group companies be liable for any special direct or indirect or consequential damages which may be incurred from the use of the information made available, even if it has been advised of the possibility of such damages. The company and its employees mentioned in these communications cannot be held liable for any error's inaccuracies and/or omission howsoever caused. Any opinion or advice if any herein is made on a general basis and is subject to change without notice. The information provided in this document may contain optimistic statements regarding future events or future financial performance of countries, markets, or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided if any in this document. This document has not been reviewed by the Monetary Authority of Singapore "MAS".

Additional Marketing Disclaimer for all other International Jurisdiction:

The content of this website is restricted in certain jurisdictions and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, by anyone in any jurisdiction in which such an offer or solicitation is not authorised or may not lawfully be made (without compliance with any registration or other legal requirements) or in which the person making such offer or solicitation is not qualified to do so or to any person to whom it is unlawful to make such offer in any jurisdiction. The above information is for general guidance only, it is the responsibility of receivers to inform themselves as to any income or other tax consequences arising in the jurisdictions in which they are resident or domiciled or have any other presence for tax purposes, as well as any foreign exchange or other fiscal, or legal or regulatory restrictions which are relevant to their particular circumstances in connection with the acquisition, holding or disposal of any securities if any mentioned in this document. This document is strictly private and confidential and may not be reproduced or use for any other purpose and not be provided to any person other than the recipient thereof. If you are not the intended recipient you must not copy, distribute, or take any action or place reliance on it. If you have received this communication by error, please notify the sender immediately. Any such information contained or discussed on the website is subject to change and Nuvama Group or any of its Directors, Employees, agents or representatives shall not have any responsibility to maintain the information made available or to supply any correction therewith. In no event will Nuvama Group or any of its Directors, Employees, agents or representatives, be liable for any special direct or indirect or consequential damages which may be incurred from the use of the information made available, even if it has been advised of the possibility of such damages. The company and its emp